Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors

Synta Pharmaceuticals

Status and phase

Unknown

Phase 1

Conditions

Solid Tumors

Treatments

Drug: STA 9090 (ganetespib)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00688116

9090-01

Details and patient eligibility

About

An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)

Full description

This is an open-label Phase 1 dose-escalation study in patients with solid tumors treated with STA-9090 (ganetespib) to evaluate for safety, tolerance and efficacy.

Enrollment

45 estimated patients

Sex

All

Ages

25+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients must be documented to be refractory or not candidates for current approved therapies. - Must have anECOG status 0-2. - Peripheral neuropathy ?2.
Must have acceptable organ and marrow function per protocol parameters.
No clinically significant ventricular arrythmias or ischemia.

Exclusion criteria

Must not be pregnant or breastfeeding. -No chemotherapy or radiation within 3 weeks..
No previous radiation to >25% of total bone marrow.
No previous high dose chemotherapy with autologous or allogeniec hematopoietic stem cell transplantation.
No primary brain tumors or active brain metastases.
No use of any investigational agents within 4 weeks.
No treatment with chronic immunosuppressants.
No uncontrolled, intercurrent illness.